Sangamo BioSciences | SGMO - Loan Capital


Sangamo BioSciences reported $0 in Loan Capital for its fiscal quarter ending in June of 2022.





Loan Capital Change Date
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
Amgen USD 51.89B 1.88B Mar/2026
Bayer EUR 31.83B 877M Dec/2025
BioCryst Pharmaceuticals USD 428.67M 234.31M Dec/2025
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Cipla INR 2.98B 454.6M Sep/2025
Clal Biotechnology ILS 25.96M 18.48M Dec/2023
Compugen USD 0 0 Dec/2024
CSL USD 10.42B 273M Dec/2025
Gilead Sciences USD 22.13B 6M Dec/2025
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Grifols EUR 9.95B 722.93M Dec/2025
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
J&J USD 37.53B 1.91B Mar/2026
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Merck USD 46.67B 77M Mar/2026
Novartis USD 37.45B 7.86B Mar/2026
Omeros USD 403.72M 27.2M Jun/2024
Pfizer USD 60.57B 1.08B Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 13.84B 1.88B Mar/2026
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Tectonic Therapeutic USD 43K 57K Dec/2025
Ultragenyx Pharmaceutical USD 1.15B 383.26M Dec/2025
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025